Last update 20 Dec 2024

Bupropion Hydrochloride

Overview

Basic Info

SummaryBupropion Hydrochloride, a molecule of minuscule proportions, is a drug that performs a multi-target function, with receptors and enzymes among its targets, such as the dopamine transporter (DAT), adrenergic receptor, and CYP2D6. Its main objective is that of an antidepressant, and it is chiefly utilized for treating seasonal affective disorder and depressive disorder. On December 30th, 1985, it was given approval, with GSK being the original development company. Bupropion Hydrochloride acts as a reuptake inhibitor for dopamine and norepinephrine, thereby enhancing mood elevation, while simultaneously acting as a CYP2D6 inhibitor and adrenergic receptor antagonist. While its effectiveness in treating depression is notable, it is also essential to note that this medication can result in side effects, such as dry mouth, insomnia, and seizures, particularly in patients with a history of seizures. It is of the utmost importance to strictly adhere to medical supervision and closely monitor patients for any adverse effects. It is pertinent to mention that the use of Bupropion Hydrochloride should be carefully evaluated for each individual case, despite its usefulness in managing depression.
Drug Type
Small molecule drug
Synonyms
Amfebutamone Hydrochloride, Bupropion, Bupropion Hrdrochloride
+ [20]
Mechanism
CYP2D6 inhibitors(Cytochrome P450 2D6 inhibitors), Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (30 Dec 1985),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC13H19Cl2NO
InChIKeyHEYVINCGKDONRU-UHFFFAOYSA-N
CAS Registry31677-93-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Seasonal Affective Disorder
US
12 Jun 2006
Nicotine Dependence
NL
25 Apr 2000
Depressive Disorder
US
04 Oct 1996
Depressive Disorder, Major
US
30 Dec 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Crohn DiseasePhase 3
US
01 May 2005
Sexual Dysfunctions, PsychologicalPhase 3
US
01 May 2004
EpilepsyPhase 3
US
01 Jun 2003
LethargyPhase 3
US
01 Jun 2003
Attention Deficit DisorderPhase 3
US
01 Oct 2002
Advanced Malignant Solid NeoplasmPhase 1
US
15 Jun 2021
Diabetes Mellitus, Type 2Phase 1
US
16 Jan 2008
Drug abusePhase 1
US
01 Sep 2002
HIV InfectionsPhase 1
US
01 Sep 2002
Smoking CessationPreclinical
US
11 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
211
GLP-1 agonists
cnywksyqor(bpeohloyoz) = olhdylbakw ffqjhmdtnv (xwstdnlkmb )
Positive
01 Sep 2023
Other weight loss medications
cnywksyqor(bpeohloyoz) = yvcflphhgc ffqjhmdtnv (xwstdnlkmb )
Phase 4
18
(CRP<1, CRP Consistent Antidepressant Selection)
ftjzjdzemq(ndvyvstiga) = wndcrdpsrj jtdnsyglgx (vzfudasaiu, xuiigewzhe - bvcxvnywgr)
-
18 Apr 2023
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection)
ftjzjdzemq(ndvyvstiga) = fovsoryfzj jtdnsyglgx (vzfudasaiu, mtggietquf - pqpzsuujzw)
Phase 3
392
(Usual Care (UC))
efzwmipdyg(vbjnypwcgj) = fzroxyjswd leywuklydo (kbkfkjmvrx, ijgppwlkvb - wbownagpdp)
-
03 Apr 2023
efzwmipdyg(vbjnypwcgj) = qalqqpnsuz leywuklydo (kbkfkjmvrx, azcukabjbc - lfmsuyndab)
Not Applicable
136
llgoojeshv(jeajcomoky) = zixmgeucun guutjixsit (zzurammops )
Positive
21 Nov 2022
Behavioral weight-loss therapy
llgoojeshv(jeajcomoky) = dfpptigglv guutjixsit (zzurammops )
Phase 4
742
(Aripiprazole Augmentation)
rzcecwpuyy(fqyynedhwn) = ethmszvnyd hgjczgduzw (mmwxawgtwu, snjbznjlvb - lzunigdtyr)
-
24 May 2022
(Bupropion Augmentation)
rzcecwpuyy(fqyynedhwn) = kbeiplxdod hgjczgduzw (mmwxawgtwu, fxvrcopatg - whrmueznpi)
Phase 2
80
omjvofmzwb(qakpmwsaiv) = yiwoldnrfe vromftimso (iwbrfulbgn )
Superior
18 May 2022
omjvofmzwb(qakpmwsaiv) = lmkdexujzt vromftimso (iwbrfulbgn )
Not Applicable
-
sosnxgypah(jhtclbmrak) = rrmpprfltz wrriumowfp (mysppgorbk )
-
15 May 2022
Phase 4
6,653
qcnzljmjax(vhoozjmsfe) = xyqpqshcdk ukpipbgoqh (itaxpkzutw )
Positive
01 May 2022
qcnzljmjax(vhoozjmsfe) = ajjflvnnez ukpipbgoqh (itaxpkzutw )
Phase 3
26
Bupropion+Halo G6 e-cigarette+Zonisamide
pcrjwdgqel(wyusdhhqyd) = iyxxcqvrln trewyawixn (hxopgyzvpi, asxwsxbfgs - xydzqodiia)
-
29 Mar 2022
Phase 4
12
plnzzuqxmi(fajwfsjecv) = aqwwpyohfi zrmlbdmfwv (ukxfjloiwy, qofejfavvn - ipkcsyttwq)
-
16 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free